Press Announcements > FDA approves new oral treatment for multiple sclerosis

Press Announcements > FDA approves new oral treatment for multiple sclerosis

The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat  relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease. Mavenclad is not recommended for MS patients with clinically isolated syndrome. Because of its safety profile, the use of Mavenclad is generally recommended for patients who have had an inadequate response to...